Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine names James Mullen as chairman

He has previously served as CEO of Patheon

Jim MullenGenome editing company Editas Medicine has appointed James Mullen as chairman of the board of directors.

Mullen has over 30 years’ experience leading biotechnology and pharmaceutical organisations on a global scale.

Previously, Mullen has served as chief executive officer of Patheon, a pharmaceutical development and manufacturing services provider, until its acquisition by Thermo Fisher Scientific last year.

Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.

Katrine Bosley, president and chief executive officer of Editas Medicine, said: “Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board.

“Jim’s extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.”

In addition, the company announced that Alexis Borisy and John Mendlein stepped down from the board.

12th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CACTUS

Founded in 2002, Cactus Communications is a fully integrated, global scholarly communications company with offices in Japan, South Korea, India,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics